Psychometric properties of Arabic-translated-related quality of life scales for people with parkinson disease: a scoping review.
Health-related quality of life
Parkinson’s disease
Quality of life
Scale validation
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
14 Sep 2024
14 Sep 2024
Historique:
received:
16
08
2023
accepted:
05
09
2024
medline:
15
9
2024
pubmed:
15
9
2024
entrez:
14
9
2024
Statut:
epublish
Résumé
Parkinson's disease (PD) substantially contributes to poor functional outcomes, loss in productivity, and poor health-related quality of life (HRQoL). Despite the existence of various scales, there is a notable gap in existing HRQoL reviews with regard to the availability of Arabic validated scales. As a response to this gap, the aim of our scoping review is to identify validated scales, focusing on their psychometric validation procedures, to contribute valuable insights to the understanding of HRQoL among the Arabic-speaking people with PD. A scoping review was conducted at the end of December 2022, using the Medline and Embase databases. The focus of this review was on examining the psychometric properties and validation procedures of included scales. Articles were included in the full-text screening process if they focused on people with PD of any age, included a scale measuring HRQoL in Arabic, and were written in English, French, or Arabic. After applying inclusion/exclusion criteria, 10 studies were selected to analyze HRQoL scales validated in people with PD. However, the PDQ-39 is the only HRQol PD specific scales validated in the Arabic language. Five studies validated in people with PD were identified in the context of instrument validation (3 generic, 1 specific validated in 2 studies). There are several HRQoL measurement scales for people with PD. However, only one specific HRQoL instrument has been validated in Arabic for people with PD. For the remaining instruments identified they were just used in people with PD without being validated in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Parkinson's disease (PD) substantially contributes to poor functional outcomes, loss in productivity, and poor health-related quality of life (HRQoL). Despite the existence of various scales, there is a notable gap in existing HRQoL reviews with regard to the availability of Arabic validated scales. As a response to this gap, the aim of our scoping review is to identify validated scales, focusing on their psychometric validation procedures, to contribute valuable insights to the understanding of HRQoL among the Arabic-speaking people with PD.
METHODS
METHODS
A scoping review was conducted at the end of December 2022, using the Medline and Embase databases. The focus of this review was on examining the psychometric properties and validation procedures of included scales. Articles were included in the full-text screening process if they focused on people with PD of any age, included a scale measuring HRQoL in Arabic, and were written in English, French, or Arabic.
RESULTS
RESULTS
After applying inclusion/exclusion criteria, 10 studies were selected to analyze HRQoL scales validated in people with PD. However, the PDQ-39 is the only HRQol PD specific scales validated in the Arabic language. Five studies validated in people with PD were identified in the context of instrument validation (3 generic, 1 specific validated in 2 studies).
CONCLUSION
CONCLUSIONS
There are several HRQoL measurement scales for people with PD. However, only one specific HRQoL instrument has been validated in Arabic for people with PD. For the remaining instruments identified they were just used in people with PD without being validated in this population.
Identifiants
pubmed: 39277745
doi: 10.1186/s12889-024-20002-0
pii: 10.1186/s12889-024-20002-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2505Informations de copyright
© 2024. The Author(s).
Références
Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–5.
pubmed: 28150045
doi: 10.1007/s00702-017-1686-y
Samii A, Nutt JG, Ransom BR. Parkinson’s Disease Lancet. 2004;363(9423):1783–93.
pubmed: 15172778
Marras C, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4:21.
pubmed: 30003140
pmcid: 6039505
doi: 10.1038/s41531-018-0058-0
al Rajeh S, et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology. 1993;12(3):164–78.
pubmed: 8272177
doi: 10.1159/000110316
Ashok PP, et al. Epidemiology of Parkinson’s disease in Benghazi, North-East Libya. Clin Neurol Neurosurg. 1986;88(2):109–13.
pubmed: 3757381
doi: 10.1016/S0303-8467(86)80005-1
Attia Romdhane N, et al. Prevalence study of neurologic disorders in Kelibia (Tunisia). Neuroepidemiology. 1993;12(5):285–99.
pubmed: 8309504
doi: 10.1159/000110330
Benamer HT, et al. Parkinson’s disease in arabs: a systematic review. Mov Disord. 2008;23(9):1205–10.
pubmed: 18442138
doi: 10.1002/mds.22041
Safiri S, et al. The burden of Parkinson’s disease in the Middle East and North Africa region, 1990–2019: results from the global burden of disease study 2019. BMC Public Health. 2023;23(1):107.
pubmed: 36642724
pmcid: 9841703
doi: 10.1186/s12889-023-15018-x
Garcia Ruiz PJ, Catalán MJ, Fernández JM, Carril. Initial motor symptoms of Parkinson disease. Neurologist. 2011;17(6 Suppl 1):S18–20.
pubmed: 22045320
doi: 10.1097/NRL.0b013e31823966b4
Wolters E. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S6–12.
pubmed: 20083010
doi: 10.1016/S1353-8020(09)70770-9
Seppi K, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(0 3):S42–80.
pubmed: 22021174
pmcid: 4020145
Seppi K, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.
pubmed: 30653247
pmcid: 6916382
doi: 10.1002/mds.27602
Kumaresan M, Khan S. Spectrum of non-motor symptoms in Parkinson’s Disease. Cureus. 2021;13(2):e13275.
pubmed: 33728210
pmcid: 7949722
Perlmutter JS. Assessment of Parkinson disease manifestations. Curr Protoc Neurosci 2009 Chapter 10: p. Unit10.1.
Váradi C. Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms. Biology (Basel), 2020. 9(5).
Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016;188(16):1157–65.
pubmed: 27221269
pmcid: 5088077
doi: 10.1503/cmaj.151179
Karceski S. Parkinson disease and mortality. Neurology. 2018;91(22):e2106–8.
pubmed: 30478081
doi: 10.1212/WNL.0000000000006565
Gonzalez MC, et al. Parkinson’s disease clinical milestones and mortality. Npj Parkinson’s Disease. 2022;8(1):58.
pubmed: 35550520
pmcid: 9098431
doi: 10.1038/s41531-022-00320-z
Poortvliet PC, et al. The Queensland Parkinson’s project: an overview of 20 years of mortality from Parkinson’s disease. J Mov Disorders. 2021;14(1):34.
doi: 10.14802/jmd.20034
Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615–22.
pubmed: 24821648
doi: 10.1002/mds.25898
Marinus J, et al. Evaluation of the Dutch version of the Parkinson’s Disease Questionnaire 39. Parkinsonism Relat Disord. 2008;14(1):24–7.
pubmed: 17702633
doi: 10.1016/j.parkreldis.2007.05.005
Kline EM, et al. Genetic and Environmental Factors in Parkinson’s Disease Converge on Immune function and inflammation. Mov Disord. 2021;36(1):25–36.
pubmed: 33314312
doi: 10.1002/mds.28411
Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson Disease: a review. JAMA. 2020;323(6):548–60.
pubmed: 32044947
doi: 10.1001/jama.2019.22360
Cuenca L, et al. Parkinson’s disease: a short story of 200 years. Histol Histopathol. 2019;34(6):573–91.
pubmed: 30540129
Parmar M, Grealish S, Henchcliffe C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. 2020;21(2):103–15.
pubmed: 31907406
doi: 10.1038/s41583-019-0257-7
Weintraub D, Mamikonyan E. The Neuropsychiatry of Parkinson Disease: a perfect storm. Am J Geriatr Psychiatry. 2019;27(9):998–1018.
pubmed: 31006550
pmcid: 7015280
doi: 10.1016/j.jagp.2019.03.002
Hoseinipalangi Z et al. A global systematic review and meta-analysis of the quality of life of patients with Parkinson’s disease. East Mediterr Health J, 2023. 29.
European Medicines. Agency. Committee for Medicinal Products for Human use (CHMP): „Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. 27 July 2005 [Last accessed 29 January 2013]. Available from: https://www.ispor.org/workpaper/research_practices/proconcepts_definitions.pdf .
U.S Department of Health and Human Services Food and Drug Administration Guidance for Industry: „Patient-Reported Outcome Measures. Use in Medical Product Development to Support Labeling Claims.December 2009 [Last accessed 29 January 2013]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf .
Sawicki-Wrzask D, Thomsen M, Bjerrum OJ. An analysis of the fixed-dose combinations authorized by the European Union, 2009–2014: a Focus on Benefit-Risk and Clinical Development conditions. Ther Innov Regul Sci. 2015;49(4):553–9.
pubmed: 30222435
doi: 10.1177/2168479014567322
Schipper H. Clinch, JJ, Olweny CLM (1996) Quality of life studies: definitions and conceptual issues, In Spilker B, editor Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven Publishers:Philadelphia. PP 11–23.
International Society for Quality of Life Research (ISOQOL).health related of quality of life research. Available in: http://www.isoqol.org/about-isoqol/what-is-health-related-quality-of-life-research
Schipper H, Olweny CJ. Quality of life studies: definitions and conceptual issues. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven; 1996. pp. 11–23.
Sanchez-Luengos I, et al. Predictors of health-related quality of life in Parkinson’s disease: the impact of overlap between health-related quality of life and clinical measures. Qual Life Res. 2022;31(11):3241–52.
pubmed: 35842497
pmcid: 9546987
doi: 10.1007/s11136-022-03187-y
Portillo MC, Haahr A, Navarta-Sánchez MV. Management, levels of support, quality of life, and social inclusion in Parkinson’s Disease: interventions, innovation, and practice development. Parkinson’s Disease. 2021;2021:1–4.
doi: 10.1155/2021/4681251
Bottomley A, et al. Current state of quality of life and patient-reported outcomes research. Eur J Cancer. 2019;121:55–63.
pubmed: 31561134
doi: 10.1016/j.ejca.2019.08.016
van den Heuvel L, et al. Personalizing decision-making for persons with Parkinson’s disease: where do we stand and what to improve? J Neurol. 2022;269(7):3569–78.
pubmed: 35084559
pmcid: 9217860
doi: 10.1007/s00415-022-10969-4
Dawoud DM, et al. Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in arabic-speaking countries. Res Social Adm Pharm. 2020;16(12):1754–9.
pubmed: 32057690
doi: 10.1016/j.sapharm.2020.01.018
Nair L, Adetayo OA. Cultural competence and Ethnic Diversity in Healthcare. Plast Reconstr Surg Glob Open. 2019;7(5):e2219.
pubmed: 31333951
pmcid: 6571328
doi: 10.1097/GOX.0000000000002219
Pelzang R, Hutchinson AM. Establishing Cultural Integrity in qualitative research: reflections from a cross-cultural study. Int J Qualitative Methods. 2018;17(1):1609406917749702.
doi: 10.1177/1609406917749702
Al Sayah F, et al. Health related quality of life measures in Arabic speaking populations: a systematic review on cross-cultural adaptation and measurement properties. Qual Life Res. 2013;22(1):213–29.
pubmed: 22350531
doi: 10.1007/s11136-012-0129-3
Martinez-Martin P, et al. Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2011;26(13):2371–80.
pubmed: 21735480
doi: 10.1002/mds.23834
Berardi A, et al. Tools to assess the quality of life in patients with Parkinson’s disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1):55–68.
pubmed: 33090885
doi: 10.1080/14737167.2021.1841638
Tricco AC, et al. PRISMA Extension for scoping reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467–73.
pubmed: 30178033
doi: 10.7326/M18-0850
Gazzard G et al. A scoping review of quality of life questionnaires in Glaucoma patients. J Glaucoma, 2021. 30(8).
Aburuz S, et al. The validity and reliability of the arabic version of the EQ-5D: a study from Jordan. Ann Saudi Med. 2009;29(4):304–8.
pubmed: 19584581
pmcid: 2841459
doi: 10.4103/0256-4947.55313
El Osta N, et al. Validation of the arabic version of the SF-36, generic questionnaire of quality of life related to health among the elderly in Lebanon. East Mediterr Health J. 2019;25(10):706–14.
pubmed: 31774136
Guermazi M, et al. Translation in Arabic, adaptation and validation of the SF-36 Health Survey for use in Tunisia. Ann Phys Rehabil Med. 2012;55(6):388–403.
pubmed: 22795246
doi: 10.1016/j.rehab.2012.05.003
Kharroubi SA et al. Examining the feasibility and acceptability of valuing the Arabic Version of SF-6D in a Lebanese Population. Int J Environ Res Public Health, 2020. 17(3).
Khoshhal S, et al. Assessment of quality of life among parents of children with congenital heart disease using WHOQOL-BREF: a cross-sectional study from Northwest Saudi Arabia. Health Qual Life Outcomes. 2019;17(1):183.
pubmed: 31842888
pmcid: 6915919
doi: 10.1186/s12955-019-1249-z
Shalash AS, et al. Non-motor symptoms as predictors of quality of life in Egyptian patients with Parkinson’s Disease: a cross-sectional study using a culturally adapted 39-Item Parkinson’s Disease Questionnaire. Front Neurol. 2018;9:357.
pubmed: 29881368
pmcid: 5976737
doi: 10.3389/fneur.2018.00357
Ahmadou TM, et al. Assessment of the quality of life in Moroccan Parkinson’s patients. Acta Neuropsychologica. 2020;18:67–76.
doi: 10.5604/01.3001.0013.9739
Coons SJ, et al. Reliability of an arabic version of the RAND-36 Health Survey and its equivalence to the US-English version. Med Care. 1998;36(3):428–32.
pubmed: 9520966
doi: 10.1097/00005650-199803000-00018
Ohaeri JU, Awadalla AW. The reliability and validity of the short version of the WHO Quality of Life Instrument in an arab general population. Ann Saudi Med. 2009;29(2):98–104.
pubmed: 19318760
pmcid: 2813624
doi: 10.4103/0256-4947.51790
AboAbat A, et al. Psychometric validation of a Saudi Arabian version of the sf-36v2 health survey and norm data for Saudi Arabia. J Patient-Reported Outcomes. 2020;4(1):67.
doi: 10.1186/s41687-020-00233-6
Emrani L, Senhaji M, Bendriss A. Measuring health-related quality of life in the population of Tetouan, Morocco, by the SF-36: normative data and the influence of gender and age. East Mediterranean Health J = La Revue De santé De La Méditerranée Orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ. 2016;22:133–41.
Shalash AS, et al. Clinical Profile of Non-motor symptoms in patients with essential tremor: impact on quality of life and age-related differences. Tremor Other Hyperkinet Mov (N Y); 2019. p. 9.
Elagib MAA, Hamid OEA. The Health-related Quality of Life of Sudanese Patients with Idiopathic Parkinson’s Disease. 2020.
Bekairy AM, et al. Validity and reliability of the arabic version of the the EuroQOL (EQ-5D). A study from Saudi Arabia. Int J Health Sci (Qassim). 2018;12(2):16–20.
pubmed: 29599689
Khedr EM, et al. Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life. Egypt J Neurol Psychiatry Neurosurg. 2020;56(1):116.
doi: 10.1186/s41983-020-00253-5
Marinus J, et al. Health related quality of life in Parkinson’s disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry. 2002;72(2):241–8.
pubmed: 11796776
pmcid: 1737742
doi: 10.1136/jnnp.72.2.241
Peto V, et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res. 1995;4(3):241–8.
pubmed: 7613534
doi: 10.1007/BF02260863
Jenkinson C, et al. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26(5):353–7.
pubmed: 9351479
doi: 10.1093/ageing/26.5.353
Auquier P, et al. [Validation of the French language version of the Parkinson’s Disease Questionnaire - PDQ-39]. Rev Neurol (Paris). 2002;158(1):41–50.
pubmed: 11938321
Hagell P, et al. Health status measurement in Parkinson’s disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord. 2003;18(7):773–83.
pubmed: 12815656
doi: 10.1002/mds.10438
Murthy V. Cadi-Soussi N. Patient reported Outcomes instruments in Schizophrenia: a review of Psychometric Properties. Open J Med Psychol. 2014;3(2):141–56. Toumi M.
doi: 10.4236/ojmp.2014.32017
Storf M. The impact of FDA and EMA guidances regarding patient reported outcomes (PRO) on the drug development and approval process. Scientific examination work to obtain the title Master. of Drug Regulatory Affairs; 2013.
Xin Y, McIntosh E. Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson’s: a systematic review. Qual Life Res. 2017;26(1):1–23.
pubmed: 27778141
doi: 10.1007/s11136-016-1428-x
Jenkinson C, et al. Cross-cultural evaluation of the Parkinson’s Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain. J Clin Epidemiol. 2003;56(9):843–7.
pubmed: 14505768
doi: 10.1016/S0895-4356(03)00148-3
Bushnell DM, Martin ML. Quality of life and Parkinson’s disease: translation and validation of the US Parkinson’s Disease Questionnaire (PDQ-39). Qual Life Res. 1999;8(4):345–50.
pubmed: 10472167
doi: 10.1023/A:1008979705027
Martínez Martín P, et al. The PDQ-39 Spanish version: reliability and correlation with the short-form health survey (SF-36). Neurologia. 1999;14(4):159–63.
pubmed: 10363490
Carod-Artal FJ, Martinez-Martin P, Vargas AP. Independent validation of SCOPA-psychosocial and metric properties of the PDQ-39 Brazilian version. Mov Disord. 2007;22(1):91–8.
pubmed: 17094102
doi: 10.1002/mds.21216
McKown S, et al. Good practices for the translation, cultural adaptation, and linguistic validation of clinician-reported outcome, observer-reported outcome, and performance outcome measures. J Patient Rep Outcomes. 2020;4(1):89.
pubmed: 33146755
pmcid: 7642163
doi: 10.1186/s41687-020-00248-z
Haro JM, et al. Understanding the impact of persistent symptoms in schizophrenia: cross-sectional findings from the Pattern study. Schizophr Res. 2015;169(1–3):234–40.
pubmed: 26431792
doi: 10.1016/j.schres.2015.09.001
Blanchard JJ, et al. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37(2):291–9.
pubmed: 20861151
doi: 10.1093/schbul/sbq104